Great Bay Bio
大湾生物
HKSTP-based 'AI + bioprocessing' company that applies AI to the manufacturing/CMC side of biologics — antibody design, cell-line development, culture-media optimization and sequence/expression optimization — i.e. the AI-in-biomanufacturing layer, not just AI drug discovery.
- Location
- Hong Kong Science Park, Pak Shek Kok · Hong Kong
- Visit window
- Best Jul 6–7 or Jul 11 · avoid Jul 8–10 (LEAP East)
- Source status
- high confidenceresearched
Next action
Prepare the private outreach route and meeting ask; keep contact details out of the app.
Why now: Visit window · Best Jul 6–7 or Jul 11 · avoid Jul 8–10 (LEAP East)
What they do
Builds AI platforms (AlfaBodY, AlfaDAX, AlfaCell, AlfaMedX/AlfaOPA, AlfaStaX) that compress the sequence-to-clinical-candidate path for biologics — AI antibody design, cell-line development, media optimization and expression/stability prediction. Runs a ~3,000 m² R&D lab + CMC platform in Hong Kong Science Park and positions as a CDMO-adjacent service/platform partner.
Why it matters
The closest AI-for-biomanufacturing match to Pure Advance's lead AI + biomanufacturing platform pillar among the HK finds — a real, revenue-generating company applying AI to cell line, media, expression and manufacturability (CMC), the same strain-to-process-to-scale-up bottleneck a microbial-biocontrol biomanufacturing play must clear. Its AI media/cell-line/expression-optimization approach is conceptually portable to fermentation/strain-engineering work, subject to confirming microbial applicability.
Visit objective & route
Get a platform demo and an exploratory 'could you AI-optimize fermentation/expression for a microbial active' conversation, ideally with a walk-through of the CMC platform — not an immediate deal.
Approach route
Direct / HK week — book the HKSTP office via the published meeting-scheduling link; pair with Insilico into one Pak Shek Kok day.
Talking points
- Does your AI media/cell-line/expression work have any microbial / fermentation applicability, or is the stack mammalian/CHO-only?
- Could you AI-optimize fermentation/expression for a microbial active ingredient?
- Can we get a walk-through of the 3,000 m² CMC platform vs a meeting-room-only visit?
- Platform demo of AlfaCell / AlfaMedX and the process/CMC de-risking value prop.
Open questions
- '~100 patents' and 'Forbes 100 to Watch' claims are self-reported — sanity-check before quoting.
- Current Series B size/close status and latest valuation (site lists 'first close' only).
- Whether the AI media/cell-line work has any microbial / fermentation applicability (stack is mammalian/CHO-centric).
- Whether a senior host is in HK during the window and can host a lab walk-through.
- Confirm the BD channel is reachable; the scheduling link may be the more reliable route.
Risks & unknowns
- Funding, patent-count and award claims are self-reported on the company site — treat headline totals as approximate.
- Stack is mammalian/CHO-centric; microbial/fermentation applicability is unconfirmed — the core question for a synbio/fermentation interest.
Private-pack boundary